Company intelligence / Profile preview

Biomind AI

Singapore, Central Singapore, Singaporebiomind.ai ↗

Ownership: Private
Employees: ~97
Development stage: Preclinical

Overview

BioMind (Singapore/China) offers AI-powered diagnostic tools with >90% accuracy across 100+ diseases, notably brain tumors, used clinically and academically. Biomind Labs (Uruguay) is a biotech R&D company advancing multiple psychedelic drug candidates through preclinical to Phase II trials for psychiatric and neurological disorders.

Therapeutic areas: EndocrinologyImmunologyOtherPsychiatryRheumatologyNeurology
Modalities: Non-pharmacological therapyAI-driven diagnosticsSmall moleculeNanoparticle/nanotech delivery systems
Industry: Biotech

Partnerships

Beijing Tiantan HospitalHanalytics Pte Ltd.AdventHealth

Beyond the preview

Go deeper on Biomind AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomind AI.

Explore the full profile